Skip to content

At ACADIA, we are committed to bringing new therapies to patients living with debilitating central nervous system disorders.

About Us

ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders.
More »


News

November 09, 2009
ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results

November 02, 2009
ACADIA Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 9, 2009

More News »

Product Candidates

We are focused on developing a portfolio consisting of our most advanced product candidates including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis in collaboration with Biovail. In addition, we have a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, and additional programs in IND-track development. More »


Company Information

Investor's Kit Request Information »
Investor Webcasts Investor Webcasts »
Email Updates Email Updates »